Breast cancer history is closely tied with the treatment of the most prominent non-elected political person in the country, the First Lady.
The updated National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology-Breast Cancer Version 1.2023 recognize Agendia Inc.’s MammaPrint UltraLow Risk result and its proven impact on patient care.
Steffi Oesterreich and Adrian V. Lee, breast cancer researchers at UPMC Hillman Cancer Center and Magee-Womens Research Institute, along with Wendie Berg, professor of radiology at UPMC Magee-Womens Hospital—all from the University of Pittsburgh School of Medicine—received funding from the Breast Cancer Research Foundation.
The FY23 Defense Appropriations Act is anticipated to provide funding for the BCRP to support innovative, high-impact research with clinical relevance that will accelerate progress to end breast cancer for service members, veterans, and the general public.
In an article published in Nature Medicine, Moffitt Cancer Center researchers, led by Hatem Soliman, share results from a phase II clinical study of the oncolytic virus talimogene laherparepvec combined with standard chemotherapy in patients with early stage triple-negative breast cancer.
Awareness of breast density appears to increase one’s perceived breast cancer risk for a short time after undergoing mammography in Northern Manhattan according to a study at Columbia University Mailman School of Public Health.
Age-based heuristics can lead to large differences in breast cancer treatment based on small differences in chronologic age, according to a new analysis of more than 500,000 patient records.
Results from the SWOG S1416 clinical trial showed that adding veliparib to chemotherapy can significantly extend progression-free survival times in patients with TNBC that has a “BRCA-like” phenotype.
FDA approved Orserdu (elacestrant) for postmenopausal women or adult men with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.
A multi-institutional team led by scientists from the Medical College of Wisconsin Cancer Center has discovered PD-L2 as a therapy-relevant marker to identify patients with estrogen receptor-positive breast cancer who may benefit from new immunotherapies.
